Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: Results from 8-year follow-up

Vaccine

Volumn 25, Issue 3, 2007, Pages 446-449

  Wang, Xuan Yi ^a,b   Xu, Zhi Yi ^a,b   Ma, Jing Chen ^c   von Seidlein, Lorenz ^a   Zhang, Yong ^d   Hao, Zhi Yong ^c   Han, Oak Pil ^a   Zhang, Ying Lin ^c   Tian, Mei Ying ^b   Ouyang, Pei Ying ^b   Zhang, Zhi Yong ^c   Han, Chang Quan ^c   Xing, Zhan Chun ^c   Chen, Ji Chao ^c  

^a International Vaccine Institute   (South Korea)

^b FUDAN UNIVERSITY   (China)

^c Zhengding Center for Disease Control and Prevention   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Booster; Hepatitis A; Live attenuated vaccine; Persistence; Single dose

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; LIVE VACCINE;

ARTICLE; CHILD; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; INFANT; MALE; VACCINES, ATTENUATED;

EID: 33845334517     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.004     Document Type: Article

References (19)

1. Center for Public Health Surveillance Information Service C. National data of class A and B infectious diseases in December 2004. Ji Bing Jian Ce 20 1 (2005) 3
2. Center for Public Health Surveillance Information Service C. Case of noticeable infectious disease (class A & B), China, December 1994. Ji Bing Jian Ce 10 1 (1995) 1
3. Li Y.T. Epidemiological manifestation and trends of hepatitis A in Shanghai. Shanghai Yu Fang Yi Xue Za Zhi 12 9 (2000) 407-408
4. Jacobsen K.H., and Koopman J.S. Declining hepatitis A seroprevalence: a global review. Epidemiol Infect 132 (2004) 1005-1022
5. Hu M.D., Scheid R., and Deinhard F. Attenuated hepatitis A virus for vaccine development. In: Zuckerman A.J. (Ed). Viral hepatitis and liver disease (1988), Alan R. Liss, New York 81-82
6. Mao J.S., Dong D.X., Zhang H.Y., Chen N.L., Zhang X.Y., Huang H.Y., et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 159 4 (1989) 621-624
7. Xu Z.Y., Li R.C., Meng Z.D., Zhang Y., Yan C.K., Zhou T.K., et al. Immunogenicity and efficacy trails of live attenuated hepatitis A vaccines. Zhong Hua Yi Xue Za Zhi 78 4 (1998) 254-256
8. Xu Z.Y., Wang X.Y., and Zhang Y. A review of studies on efficacy and immunogenicity of two live attenuated hepatitis A vaccine. Chin Med Sci J 14 Suppl. (1999) 1-4
9. 2 Strains and LA-1 strains). Zhong Hua Yi Xue Za Zhi 82 10 (2002) 678-691
10. Ma J.C., Zhang Y.L., Han C.Q., Liu H.B., Wang X.Y., Zhang Y.W., et al. A study on the efficacy of standardized China-made live attenuated hepatitis A vaccine (H2 strain). Hebei Yi Ke Da Xue Xue Bao 23 4 (2002) 213-215
11. Zaaijer H.L., Leentvaar-Kuijpers A., Rotman H., and Lelie P.N. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J Med Virol 40 1 (1993) 22-27
12. Liu Y., Ouyang P.Y., and Xu Z.Y. Quantity assay the anti-HAV using ELISA method. In: Liu X.G. (Ed). Laboratory diagnostics of viral hepatitis. 2nd ed. (1999), People's Medical Publishing House, Beijing 355-357
13. Chan C.Y., Lee S.D., Yu M.I., Wang Y.J., Chang F.Y., and Lo K.J. Long-term follow-up of hepatitis A vaccination in children. Vaccine 17 (1999) 369-372
14. Iwarson S., Lindh M., and Widerstrom L. Excellent booster response 4-6 year after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 34 2 (2002) 110-111
15. Wang X.Y., Ma J.C., Zhang Y., Zhang Y.L., Han C.Q., Xing Z.C., et al. Primary study on immunologic effect of live attenuated hepatitis A vaccine (H2 strain) after booster dose. Zhong Hua Liu Xing Bing Xue Za Zhi 21 2 (2000) 124-127
16. Damme P.V., Banatvala J., Fay O., Lwarson S., Mcmahon B., Herck K.V., et al. Hepatitis A booster vaccination: is there a need?. Lancet 362 (2003) 1065-1071
17. Herck K.V., and Damme P.V. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 4 4 (2005) 459-471
18. Wang X.Y., Ma J.C., Zhang Y., Zhang Y.L., Zhang Y.W., Han C.Q., et al. Immunogenicity and long-term persistance of anti-HAV in groups with different attenuated and inactivated hepatitis A vaccine dosage. Zhong Hua Liu Xing Bing Xue Za Zhi 22 2 (2001) 111-113
19. Wang X.Y., Xu Z.Y., Yao X., Tian M.Y., Zhou L.D., He L.F., et al. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine 22 (2004) 1941-1945